Rational design of multifunctional nanoplatforms capable of combining therapeutic effects with real-time monitoring of drug distribution and tumor status is emerging as a promising approach in cancer nanomedicine. Here, we introduce pyropheophorbide a–bisaminoquinoline conjugate lipid nanoparticles (PPBC LNPs) as a bimodal system for image-guided phototherapy in bladder cancer treatment. PPBC LNPs not only demonstrate both powerful photodynamic and photothermal effects upon light activation, but also exhibit potent autophagy blockage, effectively inducing bladder cancer cell death. Furthermore, PPBC LNPs possess remarkable photoacoustic (PA) and fluorescence (FL) imaging capabilities, enabling imaging with high-resolution, deep tissue penetration and high sensitivity for tracking drug biodistribution and phototherapy efficacy. Specifically, PA imaging confirms the efficient accumulation of PPBC LNPs within tumor and predicts therapeutic outcomes of photodynamic therapy, while FL imaging confirms their prolonged retention at the tumor site for up to 6 days. PPBC LNPs significantly suppress bladder tumor growth, with several tumors completely ablated following just two doses of the nanoparticles and laser treatment. Additionally, PPBC LNPs were formulated with lipid-based excipients and assembled using microfluidic technology to enhance biocompatibility, stability, and scalability, showing potential for clinical translation. This versatile nanoparticle represents a promising candidate for further development in bladder cancer therapy.

Men at the greatest risk of testicular cancer might not even know it. While it's considered a ‘young man’s disease,’ a survey commissioned by The Ohio State University Comprehensive Cancer Center finds nearly 90% of Americans don’t realize that testicular cancer is most common in men under the age of 40. 

Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University observe and model how the enzyme ADAR1 interacts with double-stranded RNA, which may be useful for future cancer treatment strategies.

A new study from the University of Rochester reveals that key optical measurements of tumor collagen structure differ between Black and White patients with breast and colon cancer. Using second-harmonic generation imaging, researchers analyzed collagen organization in over 300 tumor samples and found significant racial differences in a prognostic marker known as the forward-to-backward scattering ratio (F/B), which is linked to metastatic risk. These findings highlight the need for racially diverse clinical trials to ensure that emerging diagnostic tools accurately predict cancer outcomes for all patient populations.